Literature DB >> 11255325

The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey.

G Krueger1, J Koo, M Lebwohl, A Menter, R S Stern, T Rolstad.   

Abstract

BACKGROUND: Psoriasis can have a profound impact on a patient's quality of life.
OBJECTIVES: To assess patients' perspectives on the impact of psoriasis on their lifestyle and emotional well-being and the social ramifications of living with the disease; to determine the range of therapies available; and to ascertain patients' satisfaction with the management of their disease.
DESIGN: A 4-page, self-administered questionnaire was mailed on July 13 and 14, 1998, to the entire membership of the National Psoriasis Foundation (N = 40 350), and followed by a telephone survey of responders with severe psoriasis. MAIN OUTCOME MEASURES: Patients' perspectives on the psychosocial impact of psoriasis and the effectiveness of the management of their disease.
RESULTS: Of the 40 350 questionnaires mailed out, a response rate of 43% was realized. The most frequent symptoms experienced by the mail-survey respondents were scaling (94%), itching (79%), and skin redness (71%); 39% reported that psoriasis covered 10% or more of their bodies. A total of 6194 patients with severe psoriasis were entered into the database for the telephone survey. Of these, 79% reported that psoriasis had a negative impact on their lives, 40% felt frustrated with the ineffectiveness of their current therapies, and 32% reported that treatment was not aggressive enough.
CONCLUSIONS: The unprecedented response to the survey provides compelling evidence that individuals with psoriasis believe that the disease has a profound emotional and social as well as physical impact on their quality of life. Many patients with psoriasis, particularly those with severe disease, are frustrated with the management of their disease and by the perceived ineffectiveness of their therapies. Physicians may need to improve communication with their patients and should reevaluate their management of psoriasis.

Entities:  

Mesh:

Year:  2001        PMID: 11255325

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  149 in total

1.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 2.  Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities.

Authors:  Brian J Nickoloff; Frank O Nestle
Journal:  J Clin Invest       Date:  2004-06       Impact factor: 14.808

Review 3.  [A decade of biologics in dermatology].

Authors:  G Wozel; M Meurer
Journal:  Hautarzt       Date:  2012-04       Impact factor: 0.751

4.  [Pruritus and psoriasis : an important but frequently underestimated relation].

Authors:  E Weisshaar
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

5.  Computational Systems Biology of Psoriasis: Are We Ready for the Age of Omics and Systems Biomarkers?

Authors:  Tuba Sevimoglu; Kazim Yalcin Arga
Journal:  OMICS       Date:  2015-10-19

6.  How psoriasis patients perceive, obtain, and use biologic agents: Survey from an academic medical center.

Authors:  Faranak Kamangar; Leah Isip; Tina Bhutani; Madison Dennis; Misha M Heller; Eric S Lee; Hong Nie; Wilson Liao
Journal:  J Dermatolog Treat       Date:  2011-11-10       Impact factor: 3.359

Review 7.  Psoriasis--new insights into pathogenesis and treatment.

Authors:  Ulrich Mrowietz; Kristian Reich
Journal:  Dtsch Arztebl Int       Date:  2009-01-05       Impact factor: 5.594

8.  Translation and validation of the Simplified Psoriasis Index (SPI) into Brazilian Portuguese.

Authors:  Marina Resener de Morais; Gladys Aires Martins; Ricardo Romiti; Renata Elise Tonoli; André Vicente Esteves Carvalho
Journal:  An Bras Dermatol       Date:  2018 Nov/Dec       Impact factor: 1.896

9.  Remission in psoriatic arthritis.

Authors:  Kurt de Vlam; Rik J U Lories
Journal:  Curr Rheumatol Rep       Date:  2008-08       Impact factor: 4.592

10.  Patient-reported reasons for the discontinuation of commonly used treatments for moderate to severe psoriasis.

Authors:  Howa Yeung; Joy Wan; Abby S Van Voorhees; Kristina Callis Duffin; Gerald G Krueger; Robert E Kalb; Jamie D Weisman; Brian R Sperber; Bruce A Brod; Stephen M Schleicher; Bruce F Bebo; Daniel B Shin; Andrea B Troxel; Joel M Gelfand
Journal:  J Am Acad Dermatol       Date:  2012-07-28       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.